Compare with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS vs SUVEN LIFE SCIENCES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN PHARMACEUTICALS SUVEN LIFE SCIENCES SUVEN PHARMACEUTICALS/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 43.3 -14.0 - View Chart
P/BV x 11.3 19.9 56.9% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 SUVEN PHARMACEUTICALS   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    SUVEN PHARMACEUTICALS
Mar-21
SUVEN LIFE SCIENCES
Mar-21
SUVEN PHARMACEUTICALS/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs525109 481.9%   
Low Rs10319 531.8%   
Sales per share (Unadj.) Rs39.71.1 3,745.7%  
Earnings per share (Unadj.) Rs12.1-5.7 -213.9%  
Cash flow per share (Unadj.) Rs13.4-5.3 -250.9%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs46.45.6 830.5%  
Shares outstanding (eoy) m254.57127.28 200.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x7.960.6 13.1%   
Avg P/E ratio x25.9-11.3 -228.8%  
P/CF ratio (eoy) x23.5-12.0 -195.1%  
Price / Book Value ratio x6.811.5 58.9%  
Dividend payout %16.50-   
Avg Mkt Cap Rs m79,9538,168 978.8%   
No. of employees `000NANA-   
Total wages/salary Rs m762185 411.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,097135 7,491.6%  
Other income Rs m14278 183.6%   
Total revenues Rs m10,240212 4,822.7%   
Gross profit Rs m4,430-799 -554.2%  
Depreciation Rs m31643 727.9%   
Interest Rs m1179 1,239.6%   
Profit before tax Rs m4,139-775 -534.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,053-53 -1,978.8%   
Profit after tax Rs m3,086-722 -427.7%  
Gross profit margin %43.9-593.1 -7.4%  
Effective tax rate %25.46.9 370.4%   
Net profit margin %30.6-535.3 -5.7%  
BALANCE SHEET DATA
Current assets Rs m6,6651,966 339.1%   
Current liabilities Rs m3,2151,098 292.8%   
Net working cap to sales %34.2643.8 5.3%  
Current ratio x2.11.8 115.8%  
Inventory Days Days2002 8,609.9%  
Debtors Days Days370477 77.6%  
Net fixed assets Rs m9,097257 3,534.5%   
Share capital Rs m255127 200.0%   
"Free" reserves Rs m11,554584 1,979.8%   
Net worth Rs m11,808711 1,661.1%   
Long term debt Rs m3564 9,056.2%   
Total assets Rs m15,7622,223 709.0%  
Interest coverage x36.5-81.3 -44.9%   
Debt to equity ratio x00 545.2%  
Sales to assets ratio x0.60.1 1,056.6%   
Return on assets %20.3-32.0 -63.4%  
Return on equity %26.1-101.5 -25.7%  
Return on capital %35.0-107.1 -32.7%  
Exports to sales %069.1 0.0%   
Imports to sales %0547.1 0.0%   
Exports (fob) Rs mNA93 0.0%   
Imports (cif) Rs mNA737 0.0%   
Fx inflow Rs m9,90293 10,637.3%   
Fx outflow Rs m1,369737 185.7%   
Net fx Rs m8,533-644 -1,324.5%   
CASH FLOW
From Operations Rs m3,834-960 -399.3%  
From Investments Rs m-3,114558 -557.7%  
From Financial Activity Rs m-766349 -219.6%  
Net Cashflow Rs m-45-53 84.7%  

Share Holding

Indian Promoters % 60.0 60.0 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 13.8 0.9 1,572.7%  
FIIs % 8.0 0.4 1,825.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 40.0 100.0%  
Shareholders   96,532 81,475 118.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN PHARMACEUTICALS With:   BLISS GVS PHARMA  ANUH PHARMA  SHREE GANESH REMEDIES   BROOKS LAB  ADESHWAR MEDITEX  



Today's Market

Sensex Trades Over 300 Points Higher, Dow Futures Up by 71 Points(12:30 pm)

Share markets in India are presently trading on a strong note.The BSE Sensex is trading up by 377 points, up 0.6%, at 62,142 levels.

Related Views on News

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of SUVEN PHARMACEUTICALS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN PHARMACEUTICALS. Also includes updates on the valuation of SUVEN PHARMACEUTICALS.

More Views on News

Most Popular

Is it Time to Switch from Tata Power to NTPC?(Profit Hunter)

Oct 11, 2021

Given the huge run up in Tata Power, does it make sense to switch to NTPC?

This Proxy EV Stock Just got a Power Crisis Boost(Profit Hunter)

Oct 8, 2021

After months of research, I've come across few stocks that excite me far more than the mainstream electric vehicle companies.

Rs 1 Lakh Invested in These Cryptos at the Start of 2021 Became Rs...(Views On News)

Oct 8, 2021

These cryptos would have multiplied investors' wealth by as much as 10,000% in just nine months.

Top 5 'Digital India' Stocks(Views On News)

Oct 6, 2021

These companies are leading the Government's US$1 tn 'Digital India' initiative.

5 Exciting 'Unlisted' Companies and How to Play Them(Views On News)

Oct 7, 2021

Here's how you can invest in some of the most exciting start-ups of the decade.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN PHARMACEUTICALS SHARE PRICE


Oct 19, 2021 02:00 PM

TRACK SUVEN PHARMACEUTICALS

  • Track your investment in SUVEN PHARMACEUTICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS 5-YR ANALYSIS

COMPARE SUVEN PHARMACEUTICALS WITH

MARKET STATS